Last reviewed · How we verify
typical antipsychotics
At a glance
| Generic name | typical antipsychotics |
|---|---|
| Also known as | Chlormezanone, Chlorpromazine, Chlorprothixene, Flupenthixol, Fluphenazine |
| Sponsor | Canadian Network for Observational Drug Effect Studies, CNODES |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia (NA)
- Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis (NA)
- Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome (NA)
- Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial (NA)
- Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial (PHASE4)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: